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Abstract. – OBJECTIVE: We aimed to analyze 
clinical characteristics, treatment patterns, and 
prognosis of patients with reversible cerebral 
vasoconstriction syndrome (RCVS).
MATERIALS AND METHODS: Two investiga-
tors independently searched PubMed and EM-
BASE, and 191 cases were included in this 
study. Information regarding demographics, 
triggering factors, brain imaging findings, treat-
ment modalities, recurrence, and clinical out-
come was collected. 
RESULTS: The mean age of the patients was 
39.9 years, and 155 (81.2%) were female. The 
most common triggering factor for RCVS was 
an exposure to vasoactive substances (41.4%), 
followed by pregnancy/postpartum (20.9%), and 
sexual intercourse (10.5%). Multifocal stenosis 
(84.0%) and beading shape (82.4%) were the 
leading abnormal findings on angiography, while 
cerebral ischemic lesions (47.6%) and cerebral 
hemorrhage (mainly subarachnoid hemorrhage) 
(35.1%) were the main findings on brain comput-
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ed tomography (CT)/magnetic resonance imag-
ing (MRI). Calcium channel blockers (nimodip-
ine/verapamil) were the most commonly used 
medications (44.5%) in the treatment of RCVS. 
Multivariate analysis identified that RCVS was 
precipitated by trauma/surgery/procedure (haz-
ard ratio (HR): 3.29, 95% confidence interval (CI) 
(1.21-8.88), p=0.019), and presence of aphasia/
neglect/apraxia during the acute phase of the 
disease (HR: 3.83, 95% CI (1.33-11.05), p=0.013) 
were found to be the two independent risk fac-
tors for residual neurological deficit after RCVS. 
CONCLUSIONS: In our systematic review, va-
soactive substances were the most frequent 
triggers for RCVS, which was most commonly 
accompanied by angiographic findings of mul-
tifocal stenotic lesions. Patients with RCVS pre-
cipitated by trauma or surgical procedures and 
those with focal cortical deficits had a higher 
risk of residual neurological deficits, and these 
patients should closely be monitored.
Key Words:
Reversible cerebral vasoconstriction syndrome, 
Call-Fleming syndrome, Benign angiopathy of the 
central nervous system, Thunderclap headache, Re-
versible vasospasm, Migrainous vasospasm, Drug-in-
duced cerebral arteritis, Postpartum cerebral angiop-
athy, Central nervous system pseudovasculitis. 
Introduction
Reversible cerebral vasoconstriction syndrome 
(RCVS) is characterized by severe headaches, of-
ten thunderclap headaches, with or without focal 
deficits and seizures, and a multifocal constric-
tion of cerebral arteries, which generally resolves 
spontaneously within 3 months1. The thunder-
clap headaches are described by the International 
Classification of Headaches as sudden high-inten-
sity headaches, described “thunderclap” because 
they reach maximum intensity within seconds2. 
In the context of RCVS, they are triggered fre-
quently following vasoconstrictor exposure, post-
partum, or neurosurgical procedures, though it 
is possible that there may be additional triggers 
not described by the available case reports in the 
literature2. On imaging, RCVS is accompanied by 
a “string of beads” appearance of cerebral vessels 
due to the alternating, simultaneous dilatation and 
constriction, both of which (dilatation and con-
striction) resolve completely within 3 months2. 
Although RCVS predisposes toward transient 
ischemic attack, stroke, and other constrictive 
diseases of cerebral vessels, the syndrome pos-
sesses distinct factors on history and clinical 
findings. Namely, transient ischemic attacks and 
stroke involve acute neurologic defects resultant 
of underlying ischemia, while RCVS can present 
as vasoconstriction of cerebral arteries with or 
without presence of ischemia or neurologic symp-
toms. Furthermore, RCVS cannot be diagnosed 
if subarachnoid hemorrhage2. RCVS tends to 
occur over a period of one week to a month, and 
more acute symptoms that resolve more rapidly 
than this time period should raise suspicion for 
other phenomena, including transient ischemic 
attacks or cold-stimulus headaches. Recently, it 
has been argued that RCVS should be considered 
as multiple disorders accompanied by reversible 
vasoconstriction of cerebral vessels rather than a 
single disease2-4.
Before the name RCVS was proposed and the 
diagnostic criteria published in 2007, the symp-
toms of RCVS were described under various 
other names5. After the diagnostic criteria for 
RCVS were published, the diagnosis of RCVS in-
creased due to improved imaging and diagnostic 
approaches, and the number of articles related to 
this disease have continuously increased2,5,6. Al-
though RCVS has been thought to be mostly “re-
versible” with a good prognosis7,8, several stud-
ies, including large series, showed that cerebral 
infarction and/or cerebral hemorrhage were the 
main complications of this syndrome. Further-
more, this syndrome may also be accompanied by 
reversible brain edema consistent with a posteri-
or reversible encephalopathy syndrome (PRES) 
in the postpartum state9,10, suggesting that this 
syndrome may not always have a favorable or 
reversible prognosis. Furthermore, recurrence of 
RCVS has also been reported9,11-13.
Whereas the clinical features and the various 
causes of RCVS have been described in sporadic 
case reports, there have been few reports on the 
patterns of imaging, treatment options, and the 
outcomes related to prognosis. Therefore, the 
aim of this study was firstly to analyze clinical 
characteristics, treatment patterns, and prognosis 
of the patients with RCVS by a systematic review 
approach and to find the risk factors for the resid-
ual neurological deficits after RCVS events.
Materials and Methods
Search Strategy for the Literatures and 
Study Selection
We performed an English literature search to 
systematically collect the case reports of RCVS. 
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The PRISMA guidelines were followed during 
data extraction, analysis, and reporting14. Two 
investigators (JW Kang and TJ Song) inde-
pendently searched PubMed and EMBASE and 
extracted the data. Most of the articles retrieved 
from PubMed were duplicated in EMBASE. The 
search term was: “Reversible cerebral vasocon-
striction syndrome” or “RCVS”. Reports of pedi-
atric cases (below the age of 18) were not exclud-
ed. We labeled all the articles by examining titles, 
abstracts, and full texts in order, and any discrep-
ancies were discussed and resolved by consensus 
among the 3 investigators (JW Kang, TJ Song, 
and JI Shin). The detailed process of screening 
and selection of articles is presented in Figure 1 
(Supplemental References). Among these, 188 
cases showed a confirmed RCVS with multifocal 
vasoconstriction on computed tomography (CT)/
magnetic resonance imaging (MRI) or transfem-
oral angiography and normalized angiography 
within 3 months, and 3 cases had a confirmed 
RCVS by using the transcranial doppler method. 
A detailed flow-chart of screening and choosing 
eligible articles is presented in Figure 1.
Data Extraction
For each eligible case report, we extracted and 
recorded information about age, sex, ethnicity, 
potential triggers (medications and drugs, post-
partum, sexual intercourse, smoking, exercise, 
travel, blood transfusion, energy drink intake, 
upper respiratory tract infection, surgery, tumor, 
emotional stress, peritoneal dialysis, shower, and 
Valsalva), usage of specific possible provocative 
Figure 1. Flow chart of literature search.
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medications and drugs for RCVS (such as anti-
depressants, addictive drugs, sympathomimetics, 
hormone substitution, etc.), past medical history 
(such as headache, psychologic diseases, hyper-
tension, smoking, etc.), accompanying neurologic 
symptoms (such as headache, motor weakness, 
visual abnormality, seizure, mental change, etc.), 
other accompanying clinical manifestations (nau-
sea, vomiting, pain, respiratory symptoms, etc.), 
frequency and type of performed imaging mo-
dality, brain parenchymal (ischemic or hemor-
rhagic lesions) and/or angiographic (multifocal, 
hemispheric, beading, and focal stenotic pattern) 
findings from CT and/or MRI, treatment mo-
dalities (medications and/or other interventions), 
radiologic outcome (improved (recovered) or 
not-improved (or progressed)), clinical outcome 
(fully recovery or residual deficit), and recurrence 
of RCVS.
Statistical Analysis
Statistical analyses were performed using 
SPSS for Windows version 21.0 (IBM, Armonk, 
NY, USA) and MedCalc version 15.8 (MedCalc 
Software, Ostend, Belgium). The independent 
t-test was used for continuous variables and the 
Chi-square or Fisher’s exact test for categorical 
variables. To find the factors associated with the 
residual neurologic deficit, univariate and multi-
variate Cox regression analyses were performed. 
For multivariate analysis, age, sex and the factors 
with a p-value < 0.1 in univariate analysis used as 
independent variables. All differences were con-
sidered statistically significant at a p-value < 0.05. 
Results
Our literature search yielded 191 cases with 
a mean age of 39.9 ± 15.2 years (median 40, 
interquartile range 30-51 years), including 155 
females (81.2%). There were 18 cases under the 
age of 18. Ethnicity was unknown in 82.7%. Out 
of those with known ethnicity, 5.8% were Asian, 
8.4% were Caucasian, and 3.1% were African. 
All studies were published after the seminal 2007 
publication establishing set diagnostic criteria. 
Diagnostic criteria were established by individual 
case reports but consisted of (1) multifocal seg-
mental cerebral artery vasoconstriction on angi-
ography, (2) absence of aneurismal subarachnoid 
hemorrhage, (3) normal or near-normal cerebro-
spinal fluid, (4) severe, acute headaches, and (5) 
reversibility of cerebral vasoconstriction within 
12 weeks, or, if death occurs before 12 weeks, an 
autopsy rule out of other conditions that present 
with headache or stroke2.
In most patients (88.5%), RCVS was secondary 
to various triggers, while only 22 (11.5%) had no 
identifiable causes (idiopathic RCVS). The most 
common potential triggers for RCVS were expo-
sures to vasoactive medications and drugs (41.4%) 
and pregnancy/postpartum (20.9%). Twenty cases 
had a history of coitus (10.5%) as a trigger. Other 
potential triggers are listed in Table I. The most 
commonly reported provocative substances were 
antidepressants (n=20, 13.9%), addictive drugs 
(n=14, 9.7%), and sympathomimetic medications 
(n=12, 8.3%). Other possible provocative medica-
tions and drugs are listed in Supplementary Ta-
Table I. Potential triggers of reversible cerebral vasoconstriction syndrome.
 Potential triggers Total (n = 191) Detailed components of provocative factors
Medications and drugs 79 (41.4) 
Pregnancy/postpartum 40 (20.9) 
Sexual intercourse 20 (10.5) 
Smoking  7 (3.7) 
Exercise 5 (2.6) Skiing, dive, road race, lifting weights, swimming
Travel 4 (2.1) 3 Airplanes, 1 high altitude
Blood transfusion 3 (1.6) 
Energy drink intake 2 (1.0) 
Upper respiratory tract infection 2 (1.0) Uterine artery embolization, nasal sinus surgery
Surgery 2 (1.0) 
Tumor 1 (0.5) Bronchial carcinoid tumor
Emotional stress 1 (0.5) Death of friends
Peritoneal dialysis 1 (0.5) 
Shower 1 (0.5) 
Valsalva 1 (0.5) 
Unidentifiable causes 22 (11.5) 
Values are presented as number (percent). 
Reversible cerebral vasoconstriction syndrome: a comprehensive systematic review
3523
ble I. Regarding past medical history, underlying 
or preexisting headache (particularly migraine) 
was the most common (21.9%) to associate with 
RCVS, and psychological diseases (10.9%), hy-
pertension (8.3%), smoking (7.3%), and vascular 
disease (7.3%) were the major comorbid condi-
tions (Table II).
The most common neurologic symptom of 
RCVS was headache (93.2%). Others were motor 
weakness (36.6%), visual abnormality (30.4%), 
mental change (20.4%), and seizure (17.3%). Oth-
er accompanying neurologic symptoms are list-
ed in Table III. Nausea (26.7%) and vomiting 
(16.8%) were the most common accompanying 
non-neurological symptoms (see Supplementary 
Table II for detailed description).
Angiographic findings were reported for 188 
of the 191 cases (98.4%) (Supplementary Ta-
ble III) and mostly showed multifocal steno-
sis (84.0%) and beading shape (82.4%) (Table 
IV). CT/MRI revealed cerebral ischemic lesions 
(47.6%) and cerebral hemorrhage (35.1%) as lead-
ing parenchymal abnormalities. Among subjects 
with cerebral hemorrhage, subarachnoid hem-
orrhage (67.2%) was most commonly observed 
(Table IV). 
Regarding treatment modalities, calcium chan-
nel blockers (79.1%, mainly nimodipine/verapam-
il) were most commonly used in the manage-
ment of RCVS. After calcium channel blockers, 
analgesics (21.5%, mainly aspirin) and steroids 
(16.8%, mainly methylprednisolone) were most 
commonly used. Further treatment approaches 
are described in Supplementary Table IV. It was 
not uncommon for multiple medications to be 
used in combination in RCVS: 22.5% were treat-
ed with two kinds of therapy, 10.5% were treated 
with three kinds, 5.8% with four kinds, and 2.6% 
with 5 kinds. The most common treatment com-
binations were calcium channel blockers with 
Table II. Past medical histories of reversible cerebral vasoconstriction syndrome.
 Past medical histories Total (n = 191)
Headache (31 migraine, 7 unspecified, 3 sexual, 1 tension-type) 42 (21.9)
Psychologic disease (18 depression, 1 obsessive compulsive disorder, 1 bipolar, 1 anxiety) 21 (10.9)
Hypertension 16 (8.3)
Smoking 14 (7.3)
Vascular disease (2 fibromuscular dysplasia, 3 ICA stenosis or occlusion, 1 arterio-venous malformation, 14 (7.3)
1 cerebellar artery aneurysm, 1 renal artery stenosis, 1 atherosclerosis, 1 venous sinus stenosis,  
1 aortic dissection, 1 moyamoya disease, 1 cerebral infarction, 1 hepatic artery constriction) 
Respiratory disease (4 asthma, 3 upper respiratory infection, 1 tonsillitis, 1 otitis media, 1 chronic  10 (5.2)
obstructive pulmonary diseases) 
Hematologic disease (4 anemia, 3 leukemia, 1 myelodysplastic syndrome) 8 (4.2)
Cardiac disease (2 valve disease, 1 tetralogy of Fallot, 1 hypertrophic cardiomyopathy, 1 dilated  8 (4.2)
cardiomyopathy, 2 atrial fibrillation, 1 myocardial infarction) 
Dyslipidemia 8 (4.2)
Tumor (prostate, breast, retinoblastoma, ovary, melanoma, bilateral carotid paraganglioma, benign 7 (3.7)
neurinoma, each 1 case) 
Obstetric condition (2 miscarriages, menorrhagia, endometriosis, menstrual cycle disturbances,  7 (3.7)
menopause, uterine myoma) 
Autoimmune disease (3 systemic lupus erythematous, 3 multiple sclerosis, Takayasu arteritis) 7 (3.7)
Trauma (traffic accidents, spinal compression fractures, fall, tibia fracture) 6 (3.1)
Nephrologic and urologic disease (Nephrotic syndrome, bladder diverticula, neurogenic bladder, 5 (2.6)
nephrolithiasis, end-stage renal disease) 
Genetic abnormality (2 ATP1A2 gene mutation, 1 Loeys-Dietz Syndrome, 1 mitochondrial  4 (2.1)
encephalomyopathy) 
Diabetes mellitus (including gestational diabetes mellitus) 4 (2.1)
Preeclampsia (nonspecific, seizure before delivery, preeclampsia related hypertension) 3 (1.6)
Hypothyroidism 3 (1.6)
Obesity 3 (1.6)
Drug allergy 2 (1.0)
Blindness  2 (1.0)
Neuropathy 2 (1.0)
Musculo-skeletal symptom (neck pain, cervical spondylosis) 2 (1.0)
Slow transit bowel syndrome 1 (0.5)
Sleep apnea 1 (0.5)
Values are presented as number (percent).
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magnesium (4.2%), calcium channel blockers 
with anticoagulants (3.7%), and calcium channel 
blockers with steroids (3.7%). Out of the 191 cas-
es, 39.3% were treated with only one therapy. The 
remainder of treatment modality combinations 
are reported in Supplementary Table V.
Detailed data regarding clinical and imag-
ing follow-up, as well as recurrence rates, are 
described in Supplementary Table VI. Of the 
191 cases, improved abnormal finding (stenosis 
or beading) in brain imaging were noted in 155 
(81.1%) cases. Among the 155 cases, improve-
ment of abnormal finding was recorded in 149 
cases after a mean time period of 73.8 ± 89.2 
days (median 60 days). In most cases, brain 
image findings were improved within 1 to 3 
months (51.6%). Regarding neurologic symp-
toms and prognosis, 124 of the 191 cases had 
a clear description of neurologic deficit at the 
time of last follow-up (mean 42.7 ± 55.3 days, 
median 25 days). Among them, there were 26 
(20.9%) cases with prolonged neurologic deficit. 
Including cases with unclear follow up periods, 
neurologic deficits remained in 36 of the 191 
cases (18.8%). Recurrent RCVS was reported 
in 4.7% of the cases, and 66.7% of them had a 
second recurrence during follow-up. 
Comparison of demographic and associated 
factors between patients with and without re-
sidual neurologic deficit showed that older age 
(p=0.011), trauma/surgery/procedure related 
precipitating factors (p=0.029), motor weakness 
(p=0.014), and aphasia/neglect/apraxia (p=0.010) 
Table III. Accompanying neurologic symptoms of reversible cerebral vasoconstriction syndrome.
 Accompanying neurologic symptom Total (n = 191)
Any types of headache 178 (93.2)
Motor weakness (39 hemiparesis, 19 limbs, 8 face, 2 quadriplegia, 1 ptosis, 1 swallowing difficulty) 70 (36.6)
Visual abnormality (13 anopsia, 12 blurred, 12 blindness, 8 visual disturbance, 7 visual field defects,  58 (30.4)
3 diplopia, 2 nystagmus, 1 scotoma) 
Mental change (18 confusion, 7 unconsciousness, 5 comas, 3 drowsy, 3 mental change, 2 stupor,  39 (20.4)
1 somnolent) 
Seizure (15 unspecified, 12 generalized tonic-clonic, 2 status epilepticus, 2 focal, 1 generalized tonic) 32 (16.8)
Speech disturbance 30 (15.7)
Sensory deficit 26 (13.6)
Photophobia 21 (11.0)
Reflex abnormality (10 hyperreflexia, 5 Babinski sign, 4 meningeal irritation signs, 1 pyramidal  21 (11.0)
symptom, 1 areflexia) 
Phonophobia  11 (5.8)
Dizziness 10 (5.2)
Behavior abnormality (8 agitation, 2 visual hallucination) 10 (5.2)
Functional deficit (3 apraxia, 3 dysmetria, 1 amnesia, 1 spatial neglect, 1 dysequilibrium) 9 (4.7)
Gait abnormality (4 ataxia, 2 imbalance) 6 (3.1)
Meningeal irritation sign 4 (2.1)
Gaze abnormality 3 (1.6)
Abnormal motor symptom (1 bradykinesia, 1 myoclonus) 2 (1.0)
Cognitive impairment 1 (0.5)
Osmophobia 1 (0.5)
Ear fullness 1 (0.5)
Urinary retention 1 (0.5)
Values are presented as number (percent).
Values are presented as number (percent).*Brain angiogra-
phies were performed in 188 (98.4%) patients among total 
included 191 subjects. †Brain images were performed in total 
191 patients.
Table IV. Radiologic findings of reversible cerebral vaso-
constriction syndrome.
 Cases, n (%)
Angiographic findings (n = 188)* 
Multifocal stenosis 158 (84.0)
Hemispheric stenosis 16 (8.5)
Focal stenosis 12 (6.4)
Normal  2 (1.1)
Presence of beading shape  155 (82.4)
Brain image findings (n = 191)† 
Ischemic lesion  91 (47.6)
Hemorrhage  67 (35.1)
Subarachnoid hemorrhage 45 (67.2)
Intracranial hemorrhage 14 (20.9)
Subarachnoid + intracranial hemorrhage  7 (10.4)
Subdural hemorrhage 1 (1.5)
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were more frequently noted in cases with residual 
neurologic deficit (Table V). In multivariate anal-
ysis, after adjusting for age, sex, and additional 
variables associated with RCVS with a p-value < 
0.1 in univariate analysis, trauma/surgery/proce-
dure (hazard ratio: 3.29, 95% confidence interval 
(1.21-8.88), p=0.019) and aphasia/neglect/apraxia 
(hazard ratio: 3.83, 95% confidence interval (1.33-
11.05), p=0.013) remained significantly indepen-
dent predictors for residual neurologic deficit 
(Table VI).
Discussion
RCVS is a syndrome characterized by thun-
derclap headaches and multifocal constriction 
of cerebral arteries that has been associated 
with benign prognoses in most cases7,8. Howev-
er, as more cases are reported, there have been 
recent associations of RCVS with cerebral hem-
orrhage, infarction, and edema9,10. There have 
been only a handful of previous systematic and 
narrative reviews aggregating the evidence on 
RCVS. Sattar et al15 used 4 case series to iden-
tify clinical characteristics of the condition, 
with a focus on diagnostic characteristics on 
imaging and CSF analysis, but did not focus on 
predisposing factors toward unfavorable neu-
rologic outcome in RCVS patients. The most 
recent systematic review to our knowledge on 
RCVS was performed by Valencia-Mendoza 
et al16, which focused on prognostic factors in 
fatal cases in RCVS but not residual deficits 
from the disease. As it stands, there remains a 
drastic need to both further aggregate clinical 
characteristics of RCVS and identify precipi-
tating symptoms and factors for poor clinical 
outcomes. Our study is a systematic review 
analyzing all the published case reports of 
subjects with RCVS in the literature. We found 
that patients with trauma/surgery/procedure as 
precipitating factors for RCVS and aphasia/ne-
glect/apraxia as acute neurologic symptoms of 
the disorder had a poor clinical outcome with 
persistent neurologic deficits.
Clinical Manifestations/Triggers
In our analysis, RCVS occurred at various ages 
ranging from 4 months to 80 years with a female 
preponderance, which were consistent with the 
previous reports1,8,15,16. It has been reported that 
up to 60% of RCVS patients have a triggering 
or precipitating factor1,13,17-20. In our study, var-
ious kinds of triggering factors were noted in 
the vast majority of cases (90.1%). Concomitant 
medications and drugs and postpartum were the 
major precipitating factors. A higher frequency of 
secondary RCVS was observed in our systematic 
review, possibly because we included reports of 
RCVS in which the authors might preferentially 
publish new potential triggers. In general, the 
main drugs suspected for triggering RCVS are 
thought to be sympathomimetic medications used 
as nasal decongestants10,21. In our report, however, 
the most commonly reported precipitants were 
antidepressants (13.9%), followed by addictive 
drugs (9.7%) and sympathomimetic medications 
(8.3%). These proportions are higher than in the 
two large published Taiwanese and Korean series 
(antidepressants <2%; illicit drugs 0%; sympath-
omimetics 1%)17,18, and lower than in the two large 
series from France and the USA (antidepressants 
21-34%, illicit drugs 20-32%, sympathomimetics 
13%)8,19. These different proportions may reflect a 
variable susceptibility to RCVS in subjects from 
Asia and from Western countries, possibly due to 
different genetic backgrounds. Moreover, in our 
data set, one-fifth of the total cases occurred at 
postpartum, which is much higher than in other 
reports from Asia (1-5%)17,18 and Western coun-
tries (12-13%)8,19. It is thought that increased pro- 
and antiangiogenic factors in the post-partum 
period could be associated with the development 
of RCVS4.
Regarding clinical manifestations of RCVS, 
headache was the most common symptom in 
our study. Most of the headaches related to 
RCVS are severe headache or thunderclap 
headache, associated with nausea, vomiting, 
and increased blood pressure22. Visual abnor-
mality and consciousness impairment are un-
common1, which is consistent with our find-
ings. In addition to thunderclap headache in 
conjunction with RCVS, stroke, focal neurolog-
ic deficit, seizure, posterior reversible encepha-
lopathy syndrome (PRES), and cerebral edema 
may occur23. 
In our analysis, ischemic lesions were noted 
in about half of the included cases, and cerebral 
hemorrhages (mainly subarachnoid) were found 
in 35% of the cases, which comprised the two 
main causes for stroke in RCVS7,10,15,16,24-25. Risk 
factors for subarachnoid hemorrhages are report-
ed to be a history of migraine, female sex, and 
older age7,10,15,16,24-27. In addition, it should be not-
ed that cerebral hemorrhage is usually observed 
within 1 week of RCVS-related symptom onset 
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Table V. Comparison of demographic and associated factors according to clinical outcome.
 Fully recovered (n = 98) Residual deficit (n = 26) Total (n = 124) p-value
Demographic data    
Sex, female 80 (81.6) 22 (84.6) 102 (82.3) 0.723
Age 38.2 ± 14.9 46.7 ± 14.2 40.0 ± 15.1 0.011
Race    0.458
Not documented 75 (76.5) 22 (84.6) 97 (78.2) 
Asian 9 (9.2) 0 (0.0) 9 (7.3) 
Caucasian 10 (10.2) 3 (11.5) 13 (10.5) 
African 4 (4.1) 1 (3.9) 5 (4.0) 
Precipitating factors    
Offending drugs 44 (44.9) 10 (38.5) 54 (43.5) 0.556
Pregnancy/endometriosis 24 (24.5) 2 (7.7) 26 (21.0) 0.101
Sexual activity 14 (14.3) 2 (7.7) 16 (12.9) 0.519
Recent trip 4 (4.1) 0 (0.0) 4 (3.2) 0.578
Trauma/surgery/procedure 7 (7.1) 6 (23.1) 13 (10.5) 0.029
Anemia 2 (2.0) 0 (0.0) 2 (1.6) 1.000
Valsalva 4 (4.1) 1 (3.8) 5 (4.0) 1.000
Past medical history    
Migraine 24 (24.5) 6 (23.1) 30 (24.2) 1.000
Previous thunderclap or sexual headache 4 (4.1) 2 (7.7) 6 (4.8) 0.446
Hypertension 10 (10.2) 4 (15.4) 14 (11.3) 0.489
Other vascular risk factors* 17 (17.3) 5 (19.2) 22 (17.7) 0.779
Malignancy 4 (4.1) 1 (3.8) 5 (4.0) 1.000
Smoking 3 (3.1) 3 (11.5) 6 (4.8) 0.106
Anxiety/Depression 9 (9.2) 3 (11.5) 12 (9.7) 0.714
Genetic disease 6 (6.1) 0 (0.0) 6 (4.8) 0.342
Autoimmune 6 (6.1) 0 (0.0) 6 (4.8) 0.342
Asthma/UTI 2 (2.0) 2 (7.7) 4 (3.2) 0.193
Epilepsy 1 (1.0) 1 (3.8) 2 (1.6) 0.377
Accompanying neurologic symptoms    
Any type of headache 92 (93.9) 24 (92.3) 116 (93.5) 0.772
Motor weakness 31 (31.6) 15 (57.7) 46 (37.1) 0.014
Seizure/mental change 29 (29.6) 13 (50.0) 42 (33.9) 0.051
Vision related 37 (37.8) 12 (46.2) 49 (39.5) 0.436
Sensory 10 (10.2) 4 (15.4) 14 (11.3) 0.489
Aphasia/neglect/apraxia 3 (3.1) 5 (19.2) 8 (6.5) 0.010
Ataxia 2 (2.0) 2 (7.7) 4 (3.2) 0.193
Brain image findings    
PRES or ischemic lesion 47 (48.0) 15 (57.7) 62 (50.0) 0.378
Cerebral hemorrhage 32 (32.7) 8 (30.8) 40 (32.3) 1.000
Angiographic findings    
Location    0.164
Focal 5 (5.1) 3 (11.5) 8 (6.5) 
Hemispheric 5 (5.1) 4 (15.4) 9 (7.3) 
Diffuse 85 (86.7) 18 (69.2) 103 (83.1) 
Bead pattern 81 (82.7) 19 (73.1) 100 (80.6) 0.272
Treatment modality/medication    
Verapamil 20 (20.4) 6 (23.1) 26 (21.0) 0.789
Nimodipine 42 (42.9) 8 (30.8) 50 (40.3) 0.369
Labetalol 3 (3.1) 1 (3.8) 4 (3.2) 1.000
Other antihypertensive agents 23 (23.5) 9 (34.6) 32 (25.8) 0.313
Steroid 15 (15.3) 8 (30.8) 23 (18.5) 0.090
Antithrombotics 16 (16.3) 1 (3.8) 17 (13.7) 0.120
Antiepileptic drugs 10 (10.2) 3 (11.5) 13 (10.5) 1.000
Pain killer 11 (11.2) 1 (3.8) 12 (9.7) 0.457
Antianxiety/psychotics 3 (3.1) 1 (3.8) 4 (3.2) 1.000
Mannitol 2 (2.0) 0 (0.0) 2 (1.6) 1.000
Cyclophosphamide 3 (3.1) 2 (7.7) 5 (4.0) 0.281
Magnesium 8 (8.2) 0 (0.0) 8 (6.5) 0.202
Surgery 3 (3.1) 2 (7.7) 5 (4.0) 0.281
Recurrent RCVS    
Recurrence 4 (4.1) 2 (7.7) 6 (4.8) 0.605
Times    0.459
1 1 (1.0) 0 (0.0) 1 (0.8) 
2 2 (2.0) 2 (7.7) 4 (3.2) 
3 1 (1.0) 0 (0.0) 1 (0.8) 
Values are presented as number (percent). UTI: urinary tract infection, PRES: posterior reversible encephalopathy syndrome, RCVS: reversible 
cerebral vasoconstriction syndrome. Other vascular risk factors: diabetes mellitus, smoking, hyperlipidemia.
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including headache, while ischemic stroke may 
be confirmed 1 to 2 weeks after the occurrence of 
RCVS-related symptoms or even after complete 
resolution of headache1.
Treatments/Recurrence
Regarding treatment of RCVS, calcium chan-
nel blockers (nimodipine or verapamil in par-
ticular) were used in about 80% of the patients 
in our analysis. Although there has been no 
randomized clinical trial, there have been some 
reports showing that calcium channel blockers 
could relieve the symptoms of RCVS in pro-
spective or retrospective studies22,28-31. However, 
the beneficial effect of calcium channel blockers 
on cerebral vasoconstriction or stroke severity 
remains unclear1. Other treatments, such as the 
use of steroids and other medications or balloon 
angioplasty, have not been proven to be effec-
tive yet32-34. In our analysis, we could not find 
any medications or treatment modalities related 
with clinical prognosis. Further studies, including 
randomized controlled trials, are needed to deter-
mine the relationship of treatment modality and 
outcome of RCVS.
The recurrence of RCVS has rarely been re-
ported13,14,35. Although the exact rate of recur-
rence is unknown, it was found in about 4.7% of 
the cases in our systematic review, and multiple 
recurrences were not uncommon in this subset. 
In previous studies, recurrence of an episode of 
RCVS after resolution of the initial symptomatic 
period was infrequent, about 5% in one report, 
and usually manifests as an isolated thunderclap 
headache without vascular complications, such as 
hemorrhagic stroke17,35,36. Nevertheless, the exact 
recurrence rates could not be drawn from our 
analysis, since the follow-up period of most cases 
was short. Therefore, prospective studies of large 
cohorts are required to determine the recurrence 
rate.
Prognosis
The prognosis of RCVS is known to be 
favorable in most cases, since clinical and 
angiographic abnormalities generally resolve 
within several days to weeks. In particular, 
the prognosis of RCVS is dependent on the 
occurrence of stroke with potential neurologic 
deficits8,22,37, eventually leading to residual defi-
cits or even fatality9,10,22,38. Altogether, 47.6% 
of the patients in our systematic review had a 
stroke during RCVS and 6.8% were left with a 
residual deficit. We also found that trauma/sur-
gery/procedure and accompanying neurologic 
symptoms of aphasia/neglect/apraxia as pre-
cipitating factors were associated with residual 
deficits in RCVS. 
Limitations
Our study has several limitations. First, our 
study was a systematic review of case reports 
published in the literature and is, therefore, sub-
ject to multiple biases. Namely, the absence of 
prospective cohorts increases the likelihood of 
selection, publication, and reporting bias. As case 
reports vary in focus and investigator, there was 
heterogeneity in described clinical features and 
follow-up amongst reports, as well as the like-
lihood of differences in the certainty of RCVS 
diagnoses. The aforementioned biases in case 
reports made treatment effects, as well as the 
causality of triggering events and risk factors, 
difficult to assess. Second, when extracting the 
data from the case reports, it was difficult to 
organize the data set according to the pre-speci-
fied criteria, and therefore, the outcome analysis 
could not be done in all cases. Third, because it 
was difficult to obtain a data set for laboratory or 
serial brain imaging findings from each case re-
port, we could not perform the analysis regarding 
the relationship between these factors and clinical 
outcome.
Table VI. Independent risk factors for residual neurologic deficit in reversible cerebral vasoconstriction syndrome.
 HR (95% CI) p-value
Sex (female) 0.44 (0.11-1.73) 0.245
Age 1.03 (0.99-1.07) 0.057
Trauma/surgery/procedure 3.29 (1.21-8.88) 0.019
Motor weakness 1.84 (0.64-5.21) 0.251
Seizure/mental change 2.47 (0.89-6.82) 0.081
Aphasia/neglect/apraxia 3.83 (1.33-11.05) 0.013
HR: hazard ratio, CI: confidence interval.
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Conclusions
Our study analyzed the various potential trig-
gers, past medical histories, accompanying neu-
rologic symptoms, brain imaging patterns, and 
clinical outcomes in RCVS by a systematic re-
view approach. Furthermore, our study suggests 
that precipitating factors of trauma/surgery/pro-
cedure and accompanying neurologic symptoms 
of aphasia/neglect/apraxia may be associated with 
residual neurological deficits in RCVS, which are 
importantly associated with the prognosis of the 
disease.
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